search
Back to results

Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting (CaCBT+CulFI)

Primary Purpose

Psychosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
CaCBT for psychosis
Culturally adapted Family Intervention (CulFI) for psychosis
Sponsored by
Pakistan Institute of Living and Learning
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psychosis focused on measuring First Episode Psychosis, LAMIC, Family Intervention, CBT, Paksitan

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria for patient participants: Individuals of all genders aged over 18 years; diagnosis of schizophrenia confirmed by Structured Clinical Interview for DSM (SCID) meeting DSM-5 criteria for schizophrenia, schizophreniform or schizoaffective psychosis Scored at least 4 on the PANSS delusions or hallucinations items, or at least 5 on suspiciousness, persecution, or grandiosity items stable on medication for the past four weeks in contact with mental health services within 3 years of diagnosis able to demonstrate the capacity to provide informed consent to take part in the study potential participants must have a carer or relative who is also willing to participate in the study to be eligible Exclusion Criteria for patient participants: Active DSM-5 substance use disorder (except nicotine or caffeine) or dependence within the last three months A score of 5 or more on the PANSS conceptual disorganisation item Individuals who have received structured psychological intervention within the past 3 months Relevant CNS or other medical disorders that would impact participation Diagnosis of intellectual disability Unstable residential arrangements Family member/Carer participant inclusion criteria: Living with or spending at least 10 hours per week in face-to-face contact with an individual with early psychosis and assuming a caring role Age>18 years Able to give informed written consent. Family member/Carer participant exclusion criteria: Active DSM-5 substance use disorder Received psychological intervention within the past 3 months Unstable residential arrangements.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    No Intervention

    Arm Label

    CaCBT for psychosis

    CulFI Intervention

    Treatment as Usual (TAU)

    Arm Description

    CaCBT is a culturally adapted psychosocial intervention for people with early psychosis that comprises of 12 sessions. These sessions are conducted individually on a weekly basis and last 45-60 minutes

    CulFI is a culturally adapted psychosocial intervention delivered over 10 sessions of 40-60 minutes, weekly for the first 8 weeks and fortnightly for the remaining 4 weeks. Sessions are delivered to patients and their carers, though patient participation in sessions is not necessary.

    TAU will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.

    Outcomes

    Primary Outcome Measures

    Positive and Negative Syndrome Scale
    The PANSS is a structured interview use to evaluate the prevalence and severity of the positive, negative and general psychiatric symptoms of schizophrenia. The higher the score the greater symptoms severity. potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale.

    Secondary Outcome Measures

    Calgary Depression Scale for Schizophrenia
    The CDSS is a 9-items scale which evaluates depression in individuals with psychosis. The minimum score is 0 and maximum 30.Higher scores indicate greater depressive severity
    EuroQol-5 Dimensions
    EuroQol-5D (EQ- 5D) will be used to assess health-related quality of life over 5 dimensions (mobility, self-care, daily activities, pain-discomfort, anxiety and depression). Higher score indicates better quality of life.
    World Health Organization Disability Assessment Scale
    It is a self-administered questionnaire based on 36 items that measures health and disability. The scoring has three steps: Step 1 - Summing of recoded item scores within each domain. Step 2 - Summing of all six domain scores. Step 3 - Converting the summary score into a metric ranging from 0 to 100 (where 0 = no disability; 100 = full disability
    Schedule for Assessment of Insight
    The Schedule for Assessment of Insight is used to evaluate the three different aspects of insight: treatment compliance, recognition of illness and re-labelling of psychotic phenomena
    Experience of Caregiving Inventory
    The ECI is a thorough measure that assesses the experiences of caring for a family member with severe mental illness
    Carer Well-Being and Support
    The CWS is an instrument to assess the wellbeing and support of a carer
    Illness Perception Questionnaire
    The IPQ is used to evaluate carer beliefs about schizophrenia
    Generalized Anxiety Disorder
    A 7-item scale measuring anxiety. Higher score indicates higher anxiety. Score 0-4: Minimal Anxiety. Score 5-9: Mild Anxiety. Score 10-14: Moderate Anxiety. Score greater than 15: Severe Anxiety.
    Patient Health Questionnaire (PHQ-9)
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression. PHQ-9 total score for the nine items ranges from 0 to 27. Higher score indicates greater depression severity
    Cognitive Behaviour Therapy Rating Scale
    Fidelity to the manuals of the interventions will be assessed via recorded sessions using Cognitive Behaviour Therapy Rating Scale
    Cognitive Therapy for Psychosis Adherence Scale
    Therapists' adherence to the manuals of the interventions will be assessed via recorded sessions using Cognitive Therapy for Psychosis Adherence Scale
    The Psychosocial Treatment Compliance Scale (PTCS)
    This is a is a reliable and valid scale which is used to measure the compliance to psychosocial treatment of people with psychotic disorders
    Treatment Adherence Rating Scale
    This scale will be used to assess the antipsychotic medication adherence of participants
    Session Attendance Log
    A session log will be maintained for each participant to maintain record of attendance for each session of assigned intervention.

    Full Information

    First Posted
    April 3, 2023
    Last Updated
    August 25, 2023
    Sponsor
    Pakistan Institute of Living and Learning
    Collaborators
    Centre for Addiction and Mental Health
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05814913
    Brief Title
    Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting
    Acronym
    CaCBT+CulFI
    Official Title
    Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting: A Large Multi-center Randomised Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 15, 2023 (Anticipated)
    Primary Completion Date
    June 30, 2026 (Anticipated)
    Study Completion Date
    December 31, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Pakistan Institute of Living and Learning
    Collaborators
    Centre for Addiction and Mental Health

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Primary Aims: To determine the clinical efficacy of Culturally adapted Cognitive Behavioral Therapy (CaCBT) and Culturally adapted Family Intervention (CulFI) compared to Treatment As Usual (TAU) on reducing overall symptoms of psychosis in patients with First Episode Psychosis (FEP) in Pakistan. Secondary Aims: To determine the efficacy of CaCBT and CulFI compared to TAU on positive and negative symptoms of psychosis, general psychopathology, depressive symptoms, quality of life, general functioning, and insight in patients with FEP in Pakistan. To determine the efficacy of CaCBT and CulFI compared to TAU on improving carer experience, carer wellbeing, carer illness attitudes and symptoms of depression and anxiety in family and carers of patients with FEP in Pakistan. To determine the comparative effect of CaCBT and CulFI in improving patient and carer related outcomes in individuals with FEP in Pakistan. To estimate the economic impact of delivering culturally appropriate psychosocial interventions in low-resource settings To explore delivery and reach of each intervention, tolerability of intervention components, acceptability of interventions, understanding mechanism of change and developing an understanding of barriers and facilitators to future adoption using process evaluation. Study design and setting: This will be a multi-centre, assessor masked, individual, three-arm randomised controlled trial (RCT). Sample Size: The study aims to recruit a total of N=390 participants with FEP
    Detailed Description
    Family Intervention (FI) and cognitive behavior therapy (CBT) are among the most efficacious psychosocial interventions to prevent relapse in schizophrenia. However, there is limited evidence from LMICs that supports the clinical efficacy and cost-effectiveness of delivering these psychosocial interventions to individuals with FEP. We aim to determine the clinical efficacy and cost-effectiveness of Culturally adapted Cognitive Behavioral Therapy (CaCBT) and Culturally adapted Family Intervention (CulFI) compared to TAU in reducing overall symptoms of psychosis in individuals with FEP in Pakistan. The study will include 390 participants with FEP from psychiatric units of hospitals in ten centres (i.e. Karachi, Lahore, Rawalpindi, Hyderabad, Qambar Shahdakot, Shaheed Benazirabad, Sukkur, Peshawar, Quetta and Multan). Consented participants meeting eligibility criteria will be randomised in a 1:1:1 allocation to CaCBT + TAU, CulFI + TAU or TAU alone. Participants in CaCBT intervention group will receive 12-weekly one-to-one sessions. Participants in CulFI group will receive 10-weekly one-to-one sessions. Each CaCBT and CulFI session will last for approximately 1 hour. Sessions will be delivered by trained psychologists who will receive regular weekly supervision to maintain fidelity. Assessments will be carried out at baseline, months 3, 6, and 12 by trained, blinded assessors. . Process evaluation will help to build the implementation knowledge base for proposed interventions across study settings. We will conduct economic evaluations (i.e., the cost-effectiveness and cost-utility analyses) of the CaCBT and CulFI interventions, as add-on to TAU.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Psychosis
    Keywords
    First Episode Psychosis, LAMIC, Family Intervention, CBT, Paksitan

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Masking Description
    Researchers doing outcome assessment will be blind to treatment allocation
    Allocation
    Randomized
    Enrollment
    390 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    CaCBT for psychosis
    Arm Type
    Experimental
    Arm Description
    CaCBT is a culturally adapted psychosocial intervention for people with early psychosis that comprises of 12 sessions. These sessions are conducted individually on a weekly basis and last 45-60 minutes
    Arm Title
    CulFI Intervention
    Arm Type
    Experimental
    Arm Description
    CulFI is a culturally adapted psychosocial intervention delivered over 10 sessions of 40-60 minutes, weekly for the first 8 weeks and fortnightly for the remaining 4 weeks. Sessions are delivered to patients and their carers, though patient participation in sessions is not necessary.
    Arm Title
    Treatment as Usual (TAU)
    Arm Type
    No Intervention
    Arm Description
    TAU will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
    Intervention Type
    Behavioral
    Intervention Name(s)
    CaCBT for psychosis
    Intervention Description
    The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
    Intervention Type
    Behavioral
    Intervention Name(s)
    Culturally adapted Family Intervention (CulFI) for psychosis
    Intervention Description
    CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
    Primary Outcome Measure Information:
    Title
    Positive and Negative Syndrome Scale
    Description
    The PANSS is a structured interview use to evaluate the prevalence and severity of the positive, negative and general psychiatric symptoms of schizophrenia. The higher the score the greater symptoms severity. potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale.
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Secondary Outcome Measure Information:
    Title
    Calgary Depression Scale for Schizophrenia
    Description
    The CDSS is a 9-items scale which evaluates depression in individuals with psychosis. The minimum score is 0 and maximum 30.Higher scores indicate greater depressive severity
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    EuroQol-5 Dimensions
    Description
    EuroQol-5D (EQ- 5D) will be used to assess health-related quality of life over 5 dimensions (mobility, self-care, daily activities, pain-discomfort, anxiety and depression). Higher score indicates better quality of life.
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    World Health Organization Disability Assessment Scale
    Description
    It is a self-administered questionnaire based on 36 items that measures health and disability. The scoring has three steps: Step 1 - Summing of recoded item scores within each domain. Step 2 - Summing of all six domain scores. Step 3 - Converting the summary score into a metric ranging from 0 to 100 (where 0 = no disability; 100 = full disability
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Schedule for Assessment of Insight
    Description
    The Schedule for Assessment of Insight is used to evaluate the three different aspects of insight: treatment compliance, recognition of illness and re-labelling of psychotic phenomena
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Experience of Caregiving Inventory
    Description
    The ECI is a thorough measure that assesses the experiences of caring for a family member with severe mental illness
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Carer Well-Being and Support
    Description
    The CWS is an instrument to assess the wellbeing and support of a carer
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Illness Perception Questionnaire
    Description
    The IPQ is used to evaluate carer beliefs about schizophrenia
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Generalized Anxiety Disorder
    Description
    A 7-item scale measuring anxiety. Higher score indicates higher anxiety. Score 0-4: Minimal Anxiety. Score 5-9: Mild Anxiety. Score 10-14: Moderate Anxiety. Score greater than 15: Severe Anxiety.
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Patient Health Questionnaire (PHQ-9)
    Description
    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression. PHQ-9 total score for the nine items ranges from 0 to 27. Higher score indicates greater depression severity
    Time Frame
    Change in scores from baseline to months 3, 6, and 12
    Title
    Cognitive Behaviour Therapy Rating Scale
    Description
    Fidelity to the manuals of the interventions will be assessed via recorded sessions using Cognitive Behaviour Therapy Rating Scale
    Time Frame
    Fidelity will be measured after completion of the intervention ( at 3rd month)
    Title
    Cognitive Therapy for Psychosis Adherence Scale
    Description
    Therapists' adherence to the manuals of the interventions will be assessed via recorded sessions using Cognitive Therapy for Psychosis Adherence Scale
    Time Frame
    Therapists' adherence will be measured after completion of the intervention ( at 3rd month)
    Title
    The Psychosocial Treatment Compliance Scale (PTCS)
    Description
    This is a is a reliable and valid scale which is used to measure the compliance to psychosocial treatment of people with psychotic disorders
    Time Frame
    Participants' compliance with psychosocial treatment will be assessed at end of intervention (3-months)
    Title
    Treatment Adherence Rating Scale
    Description
    This scale will be used to assess the antipsychotic medication adherence of participants
    Time Frame
    Participants' adherence will be assessed at end of intervention at 3, 6 and 12 months
    Title
    Session Attendance Log
    Description
    A session log will be maintained for each participant to maintain record of attendance for each session of assigned intervention.
    Time Frame
    Session attendance for each session for 3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria for patient participants: Individuals of all genders aged over 18 years; diagnosis of schizophrenia confirmed by Structured Clinical Interview for DSM (SCID) meeting DSM-5 criteria for schizophrenia, schizophreniform or schizoaffective psychosis Scored at least 4 on the PANSS delusions or hallucinations items, or at least 5 on suspiciousness, persecution, or grandiosity items stable on medication for the past four weeks in contact with mental health services within 3 years of diagnosis able to demonstrate the capacity to provide informed consent to take part in the study potential participants must have a carer or relative who is also willing to participate in the study to be eligible Exclusion Criteria for patient participants: Active DSM-5 substance use disorder (except nicotine or caffeine) or dependence within the last three months A score of 5 or more on the PANSS conceptual disorganisation item Individuals who have received structured psychological intervention within the past 3 months Relevant CNS or other medical disorders that would impact participation Diagnosis of intellectual disability Unstable residential arrangements Family member/Carer participant inclusion criteria: Living with or spending at least 10 hours per week in face-to-face contact with an individual with early psychosis and assuming a caring role Age>18 years Able to give informed written consent. Family member/Carer participant exclusion criteria: Active DSM-5 substance use disorder Received psychological intervention within the past 3 months Unstable residential arrangements.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ameer B Khoso
    Phone
    021-35371084
    Email
    ameer.bukhsh@pill.org.pk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Omair Husain, MD
    Organizational Affiliation
    Centre for Addiction and Mental Health
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Imran B Chaudhry, MD
    Organizational Affiliation
    Pakistan Institute of Living and Learning
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting

    We'll reach out to this number within 24 hrs